crisantaspase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5216	1349719-22-7

Description:

Molecule	Description
Synonyms: crisantaspase erwinase erwinaze asparaginase Erwinia chrysanthemi	Asparaginase Erwinia chrysanthemi catalyzes the deamidation of asparagine to aspartic acid and ammonia, resulting in a reduction in circulating levels of asparagine. The mechanism of action of ERWINAZE is thought to be based on the inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting in cytotoxicity specific for leukemic cells that depend on an exogenous source of amino acid asparagine for their protein metabolism and survival. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

crisantaspase
erwinase
erwinaze
asparaginase Erwinia chrysanthemi

Asparaginase Erwinia chrysanthemi catalyzes the deamidation of asparagine to aspartic acid and ammonia, resulting in a reduction in circulating levels of asparagine. The mechanism of action of ERWINAZE is thought to be based on the inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting in cytotoxicity specific for leukemic cells that depend on an exogenous source of amino acid asparagine for their protein metabolism and survival.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 18, 2011	FDA	JAZZ PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Venoocclusive liver disease	333.07	34.75	72	3383	4763	63480804
Febrile neutropenia	284.52	34.75	135	3320	118314	63367253
Lennox-Gastaut syndrome	160.45	34.75	25	3430	252	63485315
Temporal lobe epilepsy	136.62	34.75	23	3432	388	63485179
Posterior reversible encephalopathy syndrome	118.60	34.75	42	3413	17303	63468264
Pneumatosis intestinalis	111.72	34.75	26	3429	2387	63483180
Human bocavirus infection	109.13	34.75	19	3436	394	63485173
Acute lymphocytic leukaemia recurrent	107.98	34.75	25	3430	2244	63483323
Drug interaction	105.26	34.75	92	3363	229039	63256528
Secondary immunodeficiency	103.06	34.75	22	3433	1361	63484206
Enterobacter infection	87.44	34.75	21	3434	2206	63483361
Philadelphia chromosome positive	82.86	34.75	15	3440	391	63485176
Human herpesvirus 6 infection	81.52	34.75	21	3434	2936	63482631
Gastroenteritis norovirus	73.51	34.75	18	3437	2050	63483517
Herpes simplex	71.96	34.75	24	3431	8247	63477320
Venous thrombosis	66.67	34.75	20	3435	4882	63480685
Rhinovirus infection	63.85	34.75	19	3436	4510	63481057
Therapeutic response delayed	63.57	34.75	13	3442	651	63484916
Clostridium difficile colitis	63.37	34.75	28	3427	20541	63465026
Mucormycosis	62.92	34.75	17	3438	2854	63482713
Neurotoxicity	61.77	34.75	26	3429	16964	63468603
Osteonecrosis	58.65	34.75	28	3427	24502	63461065
Hyperammonaemia	56.97	34.75	18	3437	5214	63480353
Enteritis	56.35	34.75	20	3435	8266	63477301
Neutropenia	54.84	34.75	57	3398	174948	63310619
Encephalopathy	54.65	34.75	31	3424	38589	63446978
Cerebral venous sinus thrombosis	54.33	34.75	14	3441	1958	63483609
Drug resistance	48.28	34.75	24	3431	22909	63462658
Pancreatitis	40.57	34.75	28	3427	49027	63436540
Breakthrough pain	40.02	34.75	10	3445	1236	63484331
Bacterial infection	39.84	34.75	20	3435	19479	63466088
Partial seizures	39.34	34.75	14	3441	5828	63479739
Thrombocytopenia	36.52	34.75	43	3412	151114	63334453
Ileus paralytic	34.84	34.75	12	3443	4539	63481028
Bone marrow failure	34.79	34.75	21	3434	29269	63456298

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	201.17	28.44	164	5014	136685	34815068
Venoocclusive liver disease	193.14	28.44	64	5114	7902	34943851
Posterior reversible encephalopathy syndrome	138.58	28.44	53	5125	9901	34941852
Neutropenia	93.02	28.44	115	5063	156663	34795090
Mucosal inflammation	87.02	28.44	60	5118	38562	34913191
Multiple-drug resistance	69.68	28.44	27	5151	5212	34946541
Acute lymphocytic leukaemia recurrent	64.02	28.44	22	5156	3022	34948731
Stomatitis	60.08	28.44	50	5128	42464	34909289
Glioma	58.20	28.44	13	5165	356	34951397
Osteonecrosis	55.88	28.44	32	5146	14858	34936895
Haematotoxicity	51.90	28.44	25	5153	8169	34943584
Minimal residual disease	50.75	28.44	12	5166	425	34951328
Multiple organ dysfunction syndrome	49.86	28.44	59	5119	76507	34875246
Glioblastoma multiforme	49.25	28.44	13	5165	725	34951028
Encephalopathy	46.72	28.44	40	5138	35279	34916474
Septic shock	46.18	28.44	55	5123	71779	34879974
Fungal infection	46.18	28.44	29	5149	15906	34935847
Aspiration bone marrow abnormal	45.69	28.44	9	5169	131	34951622
Large intestine infection	44.08	28.44	14	5164	1504	34950249
Haemophagocytic lymphohistiocytosis	43.71	28.44	26	5152	12947	34938806
Congenital herpes simplex infection	42.36	28.44	7	5171	34	34951719
Candida endophthalmitis	40.83	28.44	8	5170	113	34951640
Mucormycosis	40.28	28.44	19	5159	5923	34945830
Blast cells present	39.08	28.44	10	5168	493	34951260
Hyperammonaemia	39.03	28.44	19	5159	6348	34945405
Venoocclusive disease	38.91	28.44	15	5163	2852	34948901
Hepatic calcification	37.55	28.44	9	5169	338	34951415
Adrenomegaly	37.00	28.44	9	5169	360	34951393
Metamyelocyte count increased	36.59	28.44	9	5169	377	34951376
Pyrexia	36.50	28.44	120	5058	332893	34618860
Hepatotoxicity	36.13	28.44	28	5150	21457	34930296
Costal cartilage fracture	34.92	28.44	8	5170	246	34951507
Oesophageal stenosis	34.43	28.44	12	5166	1718	34950035
Pancytopenia	34.14	28.44	55	5123	95102	34856651
Adenoviral hepatitis	33.53	28.44	9	5169	535	34951218
Myelocyte count increased	31.99	28.44	8	5170	359	34951394
Systemic candida	31.84	28.44	14	5164	3712	34948041
Hypertriglyceridaemia	31.27	28.44	18	5160	8430	34943323
Brain sarcoma	31.25	28.44	5	5173	19	34951734
Enterococcal infection	29.66	28.44	18	5160	9288	34942465
Superior sagittal sinus thrombosis	29.10	28.44	7	5171	267	34951486

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	423.38	27.84	284	8739	230715	79504650
Secondary immunodeficiency	324.89	27.84	75	8948	3159	79732206
Posterior reversible encephalopathy syndrome	223.72	27.84	91	8932	26190	79709175
Mycobacterium chelonae infection	210.04	27.84	50	8973	2406	79732959
Bacterial infection	205.18	27.84	90	8933	31190	79704175
Acute lymphocytic leukaemia recurrent	150.71	27.84	44	8979	4680	79730685
Pseudomonal sepsis	147.43	27.84	46	8977	6128	79729237
Neutropenia	136.34	27.84	165	8858	287545	79447820
Human bocavirus infection	128.89	27.84	27	8996	718	79734647
Clostridium difficile colitis	128.88	27.84	66	8957	32217	79703148
Human herpesvirus 6 infection	124.00	27.84	39	8984	5331	79730034
Parainfluenzae virus infection	109.62	27.84	36	8987	5646	79729719
Pneumatosis intestinalis	109.36	27.84	37	8986	6360	79729005
Viral infection	108.54	27.84	65	8958	42951	79692414
Aspergillus infection	99.87	27.84	47	8976	19114	79716251
Abscess bacterial	92.63	27.84	21	9002	813	79734552
Fungal infection	92.34	27.84	58	8965	41690	79693675
Hyperammonaemia	89.52	27.84	37	8986	11056	79724309
Thymus hypoplasia	89.40	27.84	21	9002	952	79734413
Glioma	81.88	27.84	18	9005	604	79734761
Haematotoxicity	80.66	27.84	38	8985	15481	79719884
Oesophageal candidiasis	78.65	27.84	32	8991	9186	79726179
Coronavirus infection	77.87	27.84	30	8993	7467	79727898
Mucosal inflammation	77.61	27.84	66	8957	75514	79659851
Hepatotoxicity	76.83	27.84	56	8967	51296	79684069
Enterobacter infection	76.46	27.84	26	8997	4536	79730829
Bronchopulmonary aspergillosis	75.93	27.84	41	8982	22253	79713112
Osteonecrosis	75.87	27.84	46	8977	31049	79704316
Encephalopathy	75.72	27.84	62	8961	67335	79668030
Cytomegalovirus chorioretinitis	75.50	27.84	27	8996	5463	79729902
Lymphoid tissue hypoplasia	74.68	27.84	18	9005	912	79734453
Diffuse alveolar damage	74.24	27.84	24	8999	3580	79731785
Multiple-drug resistance	73.18	27.84	30	8993	8778	79726587
Rhinovirus infection	72.66	27.84	29	8994	7924	79727441
Cerebral venous thrombosis	72	27.84	22	9001	2731	79732634
Cytomegalovirus viraemia	68.50	27.84	32	8991	12789	79722576
Viraemia	66.91	27.84	21	9002	2848	79732517
Glioblastoma multiforme	64.87	27.84	17	9006	1211	79734154
Norovirus test positive	64.58	27.84	15	9008	647	79734718
Philadelphia chromosome positive	63.96	27.84	15	9008	675	79734690
Herpes simplex	63.82	27.84	30	8993	12157	79723208
Cystitis bacterial	63.54	27.84	15	9008	695	79734670
Multiple organ dysfunction syndrome	63.44	27.84	73	8950	120173	79615192
Hypertriglyceridaemia	62.55	27.84	30	8993	12710	79722655
Pancytopenia	60.94	27.84	84	8939	165661	79569704
Pancreatitis	58.64	27.84	54	8969	68521	79666844
Enterococcal infection	56.69	27.84	30	8993	15630	79719735
Enteritis	55.82	27.84	29	8994	14554	79720811
Septic shock	55.64	27.84	69	8954	122732	79612633
Cerebral venous sinus thrombosis	54.39	27.84	17	9006	2274	79733091
Venoocclusive disease	53.63	27.84	20	9003	4553	79730812
Bone marrow failure	53.20	27.84	45	8978	51062	79684303
Mucormycosis	51.08	27.84	23	9000	8446	79726919
Lennox-Gastaut syndrome	49.90	27.84	10	9013	212	79735153
Congenital herpes simplex infection	49.62	27.84	7	9016	12	79735353
Temporal lobe epilepsy	48.29	27.84	11	9012	435	79734930
Neurotoxicity	47.58	27.84	35	8988	32483	79702882
Disseminated aspergillosis	47.36	27.84	13	9010	1105	79734260
Pyrexia	47.31	27.84	176	8847	678533	79056832
Pain	47.12	27.84	11	9012	703791	79031574
Therapeutic response delayed	47.08	27.84	13	9010	1129	79734236
Fatigue	44.63	27.84	25	8998	929702	78805663
Leukaemia recurrent	43.33	27.84	15	9008	2759	79732606
Lymphopenia	42.71	27.84	32	8991	30525	79704840
Myelopathy	42.68	27.84	17	9006	4616	79730749
Haemophagocytic lymphohistiocytosis	42.48	27.84	28	8995	21809	79713556
Ileus paralytic	42.27	27.84	21	9002	9599	79725766
Gastroenteritis norovirus	41.67	27.84	15	9008	3091	79732274
Thrombocytopenia	41.28	27.84	92	8931	265167	79470198
Pseudomonas infection	41.14	27.84	27	8996	20876	79714489
Candida endophthalmitis	39.99	27.84	8	9015	168	79735197
Hepatic calcification	39.33	27.84	9	9014	363	79735002
Sepsis	39.21	27.84	91	8932	269337	79466028
Encephalitis	39.02	27.84	23	9000	14737	79720628
Adrenomegaly	38.44	27.84	9	9014	402	79734963
Venoocclusive liver disease	38.27	27.84	21	9002	11750	79723615
Seizure	38.21	27.84	73	8950	188761	79546604
Large intestine infection	37.68	27.84	14	9009	3155	79732210
Hyperglycaemia	37.57	27.84	43	8980	70292	79665073
Neoplasm recurrence	37.22	27.84	15	9008	4199	79731166
Costal cartilage fracture	36.61	27.84	8	9015	261	79735104
Adenoviral hepatitis	35.69	27.84	10	9013	917	79734448
Venous thrombosis	35.67	27.84	17	9006	7099	79728266
Blast cells present	35.58	27.84	10	9013	927	79734438
Inappropriate antidiuretic hormone secretion	35.54	27.84	27	8996	26286	79709079
Metamyelocyte count increased	34.48	27.84	9	9014	631	79734734
Fall	33.85	27.84	7	9016	487622	79247743
Pancreatitis acute	32.90	27.84	34	8989	49570	79685795
Stomatitis	32.51	27.84	59	8964	146698	79588667
Brain sarcoma	32.01	27.84	5	9018	22	79735343
Hypofibrinogenaemia	31.94	27.84	11	9012	1991	79733374
Intracardiac thrombus	30.23	27.84	13	9010	4280	79731085
Oesophageal stenosis	30.05	27.84	13	9010	4341	79731024
Superior sagittal sinus thrombosis	29.96	27.84	9	9014	1054	79734311
Cerebral haemangioma	29.86	27.84	6	9017	129	79735236
Dyspnoea	29.73	27.84	32	8991	856993	78878372
Haemangioma	29.37	27.84	11	9012	2534	79732831
Diarrhoea	29.32	27.84	34	8989	880455	78854910
Myelocyte count increased	28.26	27.84	8	9015	761	79734604
Leukoencephalopathy	28.16	27.84	15	9008	7914	79727451

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000970	Antineoplastic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute lymphoid leukemia	indication	91857003	DOID:9952

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
C3255208	UMLSCUI
CHEMBL2108931	ChEMBL_ID
DB08886	DRUGBANK_ID
D10517	KEGG_DRUG
CHEMBL1863514	ChEMBL_ID
7347	IUPHAR_LIGAND_ID
186148	MMSL
73540	MMSL
d05689	MMSL
004466	NDDF
370893003	SNOMEDCT_US
398689003	SNOMEDCT_US
D001215	MESH_DESCRIPTOR_UI
9538	INN_ID
1232186	RXNORM
D733ET3F9O	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERWINASE	HUMAN PRESCRIPTION DRUG LABEL	1	81561-413	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10000 [iU]	INTRAMUSCULAR	Unapproved drug for use in drug shortage	3 sections